A nineteen gene-based risk score classifier predicts prognosis of colorectal cancer patients

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1653-1666

  Kim, Seon Kyu ^a   Kim, Seon Young ^a   Kim, Jeong Hwan ^a   Roh, Seon Ae ^b,c   Cho, Dong Hyung ^c,d   Kim, Yong Sung ^a,c   Kim, Jin Cheon ^b,c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Asan Medical Center   (South Korea)

^d Kyung Hee University   (South Korea)

Author keywords

Chemotherapy; Colorectal cancer; Markers; Metastasis; Prognosis

Indexed keywords

CAPECITABINE; CONNECTIVE TISSUE GROWTH FACTOR; FLUOROURACIL; OXALIPLATIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; CLASSIFIER; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC VARIABILITY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; INTRACELLULAR SIGNALING; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RNA SEQUENCE; SCORING SYSTEM; SOMATIC MUTATION; TCA19 CLASSIFIER; TREATMENT RESPONSE;

EID: 84911961534     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.06.016     Document Type: Article

References (50)

1. Acharyya S., Oskarsson T., Vanharanta S., Malladi S., Kim J., Morris P.G., Manova-Todorova K., Leversha M., Hogg N., Seshan V.E., Norton L., Brogi E., Massague J. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012, 150:165-178.
2. Aggarwal B.B., Sung B. Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol. Sci. 2009, 30:85-94.
3. Amorena M., Visciano P., Giacomelli A., Marinelli E., Sabatini A.G., Medrzycki P., Oddo L.P., De Pace F.M., Belligoli P., Di Serafino G., Saccares S., Formato G., Langella V., Perugini M. Monitoring of levels of polycyclic aromatic hydrocarbons in bees caught from beekeeping: remark 1. Vet. Res. Commun. 2009, 33(Suppl 1):165-167.
4. Binder B.R., Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol. Lett. 2008, 118:116-124.
5. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.
6. Carlsson U., Lasson A., Ekelund G. Recurrence rates after curative surgery for rectal carcinoma, with special reference to their accuracy. Dis. Colon Rectum 1987, 30:431-434.
7. Cascione L., Gasparini P., Lovat F., Carasi S., Pulvirenti A., Ferro A., Alder H., He G., Vecchione A., Croce C.M., Shapiro C.L., Huebner K. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One 2013, 8:e55910.
8. Clark-Langone K.M., Sangli C., Krishnakumar J., Watson D. Translating tumor biology into personalized treatment planning: analytical performance characteristics of the Oncotype DX colon cancer assay. BMC Cancer 2010, 10:691.
9. Cunningham D., Atkin W., Lenz H.J., Lynch H.T., Minsky B., Nordlinger B., Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047.
10. de Sousa E.M.F., Colak S., Buikhuisen J., Koster J., Cameron K., de Jong J.H., Tuynman J.B., Prasetyanti P.R., Fessler E., van den Bergh S.P., Rodermond H., Dekker E., van der Loos C.M., Pals S.T., van de Vijver M.J., Versteeg R., Richel D.J., Vermeulen L., Medema J.P. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011, 9:476-485.
11. De Sousa E.M.F., Wang X., Jansen M., Fessler E., Trinh A., de Rooij L.P., de Jong J.H., de Boer O.J., van Leersum R., Bijlsma M.F., Rodermond H., van der Heijden M., van Noesel C.J., Tuynman J.B., Dekker E., Markowetz F., Medema J.P., Vermeulen L. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 2013, 19:614-618.
12. Fan F., Samuel S., Evans K.W., Lu J., Xia L., Zhou Y., Sceusi E., Tozzi F., Ye X.C., Mani S.A., Ellis L.M. Overexpression of snail induces epithelial-mesenchymal transition and a cancer stem cell-like phenotype in human colorectal cancer cells. Cancer Med. 2012, 1:5-16.
13. Findlay V.J., Wang C., Watson D.K., Camp E.R. Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer. Cancer Gene Ther 2014, 21:181-187.
14. Hari D.M., Leung A.M., Lee J.H., Sim M.S., Vuong B., Chiu C.G., Bilchik A.J. AJCC Cancer Staging Manual 7(th) Edition criteria for Colon Cancer: do the complex modifications improve prognostic assessment?. J.Am. Coll. Surg. 2013, 217:181-190.
15. Heagerty P.J., Lumley T., Pepe M.S. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000, 56:337-344.
16. Huang L.Y., Shi H.Z., Liang Q.L., Wu Y.B., Qin X.J., Chen Y.Q. Expression of soluble triggering receptor expression on myeloid cells-1 in pleural effusion. Chin. Med. J. 2008, 121:1656-1661.
17. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
18. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
19. Jorissen R.N., Gibbs P., Christie M., Prakash S., Lipton L., Desai J., Kerr D., Aaltonen L.A., Arango D., Kruhoffer M., Orntoft T.F., Andersen C.L., Gruidl M., Kamath V.P., Eschrich S., Yeatman T.J., Sieber O.M. Metastasis-associated gene expression changes predict poor outcomes in patients with Dukes stage B and C colorectal cancer. Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research 2009, 15:7642-7651.
20. Kang G.H. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch. Pathol. Lab. Med. 2011, 135:698-703.
21. Kim S.M., Leem S.H., Chu I.S., Park Y.Y., Kim S.C., Kim S.B., Park E.S., Lim J.Y., Heo J., Kim Y.J., Kim D.G., Kaseb A., Park Y.N., Wang X.W., Thorgeirsson S.S., Lee J.S. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 2012, 55:1443-1452.
22. Kim Y.S., Kim S.H., Kang J.G., Ko J.H. Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression. BMB Reports 2012, 45:623-628.
23. Kruger A., Fata J.E., Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp-1 transgenic mice. Blood 1997, 90:1993-2000.
24. Ladwa R., Pringle H., Kumar R., West K. Expression of CTGF and Cyr61 in colorectal cancer. J.Clin. Pathol. 2011, 64:58-64.
25. Laurie J.A., Moertel C.G., Fleming T.R., Wieand H.S., Leigh J.E., Rubin J., McCormack G.W., Gerstner J.B., Krook J.E., Malliard J., et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J.Clin. Oncol. 1989, 7:1447-1456.
26. Liu X., Yu X., Zack D.J., Zhu H., Qian J. TiGER: a database for tissue-specific gene expression and regulation. BMC Bioinformatics 2008, 9:271.
27. Liu Y., Thor A., Shtivelman E., Cao Y., Tu G., Heath T.D., Debs R.J. Systemic gene delivery expands the repertoire of effective antiangiogenic agents. J.Biol. Chem. 1999, 274:13338-13344.
28. Malik G., Knowles L.M., Dhir R., Xu S., Yang S., Ruoslahti E., Pilch J. Plasma fibronectin promotes lung metastasis by contributions to fibrin clots and tumor cell invasion. Cancer Res. 2010, 70:4327-4334.
29. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
30. Marisa L., de Reynies A., Duval A., Selves J., Gaub M.P., Vescovo L., Etienne-Grimaldi M.C., Schiappa R., Guenot D., Ayadi M., Kirzin S., Chazal M., Flejou J.F., Benchimol D., Berger A., Lagarde A., Pencreach E., Piard F., Elias D., Parc Y., Olschwang S., Milano G., Laurent-Puig P., Boige V. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013, 10:e1001453.
31. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur. J. Cancer 2005, 41:1690-1696. Statistics Subcommittee of the, N.C.I.E.W.G.o.C.D.
32. Midgley R., Kerr D. Colorectal cancer. Lancet 1999, 353:391-399.
33. Midgley R.S., Yanagisawa Y., Kerr D.J. Evolution of nonsurgical therapy for colorectal cancer. Nature clinical practice. Gastroenterol. Hepatol. 2009, 6:108-120.
34. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., Ungerleider J.S., Emerson W.A., Tormey D.C., Glick J.H., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N.Engl. J. Med. 1990, 322:352-358.
35. Nakagawa H., Liyanarachchi S., Davuluri R.V., Auer H., Martin E.W., de la Chapelle A., Frankel W.L. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004, 23:7366-7377.
36. Oh S.C., Park Y.Y., Park E.S., Lim J.Y., Kim S.M., Kim S.B., Kim J., Kim S.C., Chu I.S., Smith J.J., Beauchamp R.D., Yeatman T.J., Kopetz S., Lee J.S. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012, 61:1291-1298.
37. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N.Engl. J. Med. 2004, 351:2817-2826.
38. Park Y.Y., Lee S.S., Lim J.Y., Kim S.C., Kim S.B., Sohn B.H., Chu I.S., Oh S.C., Park E.S., Jeong W., Kim S.S., Kopetz S., Lee J.S. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One 2013, 8:e60778.
39. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010, 26:139-140.
40. Sadanandam A., Lyssiotis C.A., Homicsko K., Collisson E.A., Gibb W.J., Wullschleger S., Ostos L.C., Lannon W.A., Grotzinger C., Del Rio M., Lhermitte B., Olshen A.B., Wiedenmann B., Cantley L.C., Gray J.W., Hanahan D. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19:619-625.
41. Schenk M., Bouchon A., Seibold F., Mueller C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J.Clin. Invest. 2007, 117:3097-3106.
42. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., Hernandez N.S., Chen X., Ahmed S., Konishi K., Hamilton S.R., Issa J.P. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:18654-18659.
43. Sinicrope F.A., Foster N.R., Thibodeau S.N., Marsoni S., Monges G., Labianca R., Kim G.P., Yothers G., Allegra C., Moore M.J., Gallinger S., Sargent D.J. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J.Natl. Cancer. Inst. 2011, 103:863-875.
44. Stange D.E., Engel F., Longerich T., Koo B.K., Koch M., Delhomme N., Aigner M., Toedt G., Schirmacher P., Lichter P., Weitz J., Radlwimmer B. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain. Gut 2010, 59:1236-1244.
45. Sveen A., Nesbakken A., Agesen T.H., Guren M.G., Tveit K.M., Skotheim R.I., Lothe R.A. Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?. Clin. Cancer Res. 2013, 19:6669-6677.
46. Thiery J.P., Sleeman J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 2006, 7:131-142.
47. Valastyan S., Chang A., Benaich N., Reinhardt F., Weinberg R.A. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev. 2011, 25:646-659.
48. Venables W.N., Ripley B.D., Venables W.N. Modern Applied Statistics with S 2002, Springer, New York. fourth ed.
49. Verbeek J. Moose Consort Strobe and Miame Stard Remark or how can we improve the quality of reporting studies. Scand. J. Work Environ. Health 2008, 34:165-167.
50. Yang M.H., Lin B.R., Chang C.H., Chen S.T., Lin S.K., Kuo M.Y., Jeng Y.M., Kuo M.L., Chang C.C. Connective tissue growth factor modulates oral squamous cell carcinoma invasion by activating a miR-504/FOXP1 signalling. Oncogene 2012, 31:2401-2411.